ICAP

Eswatini Prevention Center

Where We Work Eswatini CRS

Eswatini Prevention Center

In Eswatini, ICAP, in collaboration with the Eswatini Ministry of Health and Family Life Association of Eswatini, established the Eswatini Prevention Center Clinical Research Site (Eswatini CRS). This pioneer CRS has the capacity to conduct clinical trials with investigational drugs and registered products. The clinical research is implemented in close collaboration with local stakeholders to strengthen clinical research systems and conduct studies that impact local and global public health programs. Over 2,400 participants from diverse populations have been enrolled in CRS studies and participated in studies relating to HIV prevention with oral and injectable pre-exposure prophylaxis (PrEP), COVID-19 vaccination, and HPV vaccination.

Download Country Brief
Two people wearing face masks are seated at a table with medical forms, a smartphone, and medical supplies. One person in a blue jacket faces the camera, while the other in a blue gown is turned away, focused on the paperwork.

Eswatini CRS Projects

CoVPN 3008: UBUNTU Study

  • current
The UBUNTU study is a research study evaluating the Moderna COVID-19 mRNA vaccine. We already know that this vaccine prevents COVID-19 disease, including severe COVID-19. The United States and many other countries use the Moderna vaccine. We want to know how many doses of vaccine are needed for protection against COVID-19 for adults living with ...
Learn More

HPTN 084 OLE Study

  • current
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women Link: https://www.hptn.org/research/studies/hptn084 ...
Learn More

HPTN 084 Open Access

  • current
The purpose of this study is to evaluate eligible participants who have completed DAIDS-sponsored pre-exposure prophylaxis (PrEP) studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnoses, SAEs, Grade 3 and Grade 4 ISRs, and AEs leading to withdrawal. ...
Learn More

HPTN 104

  • current
A multisite, open-label, randomized crossover study comparing adherence to a single daily dual prevention pill (DPP) versus FTC/TDF and Combined Oral Contraception separate pill dosing (2PR), given for pre-exposure prophylaxis and pregnancy prevention in people of childbearing potential. The purpose of the study is to evaluate adherence to a single, dual prevention pill (DPP; co-formulated ...
Learn More

HPV Vaccine Study

  • current
A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults Living with HIV in Eswatini ...
Learn More

Site Leader

A woman with a bright smile stands against a plain white background. She has wavy, shoulder-length hair swept to one side and is wearing a black top with blue sleeves and a cowl neckline. She is also wearing small, pearl-like earrings. Harriet Nuwagaba-Biribonwoha, MD, PhD

Harriet Nuwagaba-Biribonwoha is an assistant professor of epidemiology at Columbia University’s Mailman School of Public Health and is the research director for ICAP in Eswatini. She led the second and third Population-based HIV Impact Assessment surveys in Eswatini, as well as the 2022 Violence Against Children and Youth Survey in Eswatini. Biribonwoha is leading surveillance programs that provide real-time visualization of HIV recent infections and COVID-19 infections and is the Eswatini Prevention Centre Clinical Research Site leader, overseeing a portfolio of clinical research on HIV, COVID-19, and HPV/cervical cancer prevention.

Recent ICAP News